4-yl]-5,6,7,8-tetrahydroquinolin-5-ol,
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-2-[1-(5-methylthiopyrimidin-2-yl)piperidin-4-yl]-5,6,7,8-tetrahydroquinolin-5-ol,
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-2-{1-[5-(methylsulphonyl)pyrimidin-2-yl]piperidin-4-yl}-5,6,7,8-tetrahydroquinolin-5-ol,
(5S)-2-{1-[5-(3-Carboxyphenyl)pyrimidin-2-yl]piperidin-4-yl}-4-(4,4-difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol,
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-(1-{5-[(2-hydroxyethyl)(methyl)amino]pyrimidin-2-yl}piperidin-4-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol, and
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-(1-{5-[(3S)-3-hydroxypyrrolidin-1-yl]pyrimidine-2-yl}piperidin-4-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

16. A pharmaceutical composition comprising the compound according to any one of claims 1 to 15 or a pharmacologically acceptable salt thereof as an active ingredient.

17. The pharmaceutical composition according to claim 16 for treatment or prophylaxis of dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease, cerebrovascular disease, peripheral vascular disease or obesity.

18. The pharmaceutical composition according to claim 16 for treatment or

prophylaxis of dyslipidemia, low HDL cholesterolemia, arteriosclerosis or coronary heart disease.

19. The pharmaceutical composition according to claim 16 for treatment or prophylaxis of low HDL cholesterolemia.

20. The pharmaceutical composition according to claim 16 for treatment or prophylaxis of arteriosclerosis.

21. The pharmaceutical composition according to claim 16 for treatment or prophylaxis of a disease caused by a decrease in the blood concentration of HDL cholesterol.

22. The pharmaceutical composition according to claim 16 for treatment or prophylaxis of a disease caused by an increase in the blood concentration of LDL cholesterol.

23. A medicament for inhibiting CETP comprising the compound according to any one of claims 1 to 15 or a pharmacologically acceptable salt thereof as an active ingredient.

24. A medicament for increasing the concentration of HDL cholesterol comprising the compound according to any one of claims 1 to 15 or a pharmacologically acceptable salt thereof as an active ingredient.

25. A medicament for decreasing the concentration of LDL cholesterol comprising the compound according to any one of claims 1 to 15 or a pharmacologically acceptable

salt thereof as an active ingredient.

26. Use of the compound according to any one of claims 1 to 15 or a pharmacologically acceptable salt thereof for preparing a pharmaceutical composition.

27. The use according to claim 26 for preparing a pharmaceutical composition for treatment or prophylaxis of dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease, cerebrovascular disease, peripheral vascular disease or obesity.

28. The use according to claim 26 for preparing a pharmaceutical composition for treatment or prophylaxis of dyslipidemia, low HDL cholesterolemia, arteriosclerosis or coronary heart disease.

29. The use according to claim 26 for preparing a pharmaceutical composition for treatment or prophylaxis of low HDL cholesterolemia.

30. The use according to claim 26 for preparing a pharmaceutical composition for treatment or prophylaxis of arteriosclerosis.

31. The compound according to any one of claims 1 to 15 or a pharmacologically acceptable salt thereof for use in a method of treatment or prophylaxis of a disease.

32. The compound according to claim 31 or a pharmacologically acceptable salt thereof, wherein the disease is dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis,

arteriosclerotic heart disease, coronary heart disease, cerebrovascular disease, peripheral vascular disease or obesity.

33. The compound according to claim 31 or a pharmacologically acceptable salt thereof, wherein the disease is dyslipidemia, low HDL cholesterolemia, arteriosclerosis or coronary heart disease.

34. The compound according to claim 31 or a pharmacologically acceptable salt thereof, wherein the disease is low HDL cholesterolemia.

35. The compound according to claim 31 or a pharmacologically acceptable salt thereof, wherein the disease is arteriosclerosis.

4-yl]-5,6,7,8-tetrahydroquinolin-5-ol,

(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-2-[1-(5-methylthiopyrimidin-2-yl)piperidin-4-yl]-5,6,7,8-tetrahydroquinolin-5-ol,

(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-2-{1-[5-(methylsulphonyl)pyrimidin-2-yl]piperidin-4-yl}-5,6,7,8-tetrahydroquinolin-5-ol,

(5S)-2-{1-[5-(3-Carboxyphenyl)pyrimidin-2-yl]piperidin-4-yl}-4-(4,4-difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol,

(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-(1-{5-[(2-hydroxyethyl)(methyl)amino]pyrimidin-2-yl}piperidin-4-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol, and

(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-(1-{5-[(3S)-3-hydroxypyrrolidin-1-yl]pyrimidin-2-yl}piperidin-4-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

16. The compound according to claim 2 or a pharmacologically acceptable salt thereof, which is:

(5S)-4-(4,4-Difluorocyclohexyl)-2-[1-(5-{[(2S)-2,3-dihydroxypropyl]oxy}pyrimidin-2-yl)piperidin-4-yl]-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

17. The compound according to claim 2 or a pharmacologically acceptable salt thereof, which is:

(5S)-4-(4,4-Difluorocyclohexyl)-2-[1-(5-{[(2R)-2,3-dihydroxypropyl]oxy}pyrimidin-2-yl)piperidin-4-yl]-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,

8-tetrahydroquinolin-5-ol.

18. The compound according to claim 2 or a pharmacologically acceptable salt thereof, which is:
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-{1-[5-(3-hydroxy-3-methylbutoxy)pyrimidin-2-yl]piperidin-4-yl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

19. The compound according to claim 2 or a pharmacologically acceptable salt thereof, which is:
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-2-(1-{5-[3-(methylsulphonyl)propoxy]pyrimidin-2-yl}piperidin-4-yl)-5,6,7,8-tetrahydroquinolin-5-ol.

20. The compound according to claim 2 or a pharmacologically acceptable salt thereof, which is:
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-(1-{5-[3-hydroxy-2-(hydroxymethyl)propoxy]pyrimidin-2-yl}piperidin-4-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

21. The compound according to claim 2 or a pharmacologically acceptable salt thereof, which is:
(5S)-4-(4,4-Difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-2-(1-{5-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyrimidin-2-yl}piperidin-4-yl)-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

22. The compound according to claim 2 or a pharmacologically acceptable salt

thereof, which is:

(5S)-2-{1-[5-(3-Carboxyphenyl)pyrimidin-2-yl]piperidin-4-yl}-4-(4,4-difluorocyclohexyl)-3-{(S)-fluoro[4-(trifluoromethyl)phenyl]methyl}-7,7-dimethyl-5,6,7,8-tetrahydroquinolin-5-ol.

23. A pharmaceutical composition comprising the compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof as an active ingredient.

24. Use of a compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof in the manufacture of a medicament.

25. The use according to claim 24, wherein the medicament is for the treatment or prophylaxis of dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease, cerebrovascular disease, peripheral vascular disease or obesity.

26. The use according to claim 24, wherein the medicament is for the treatment or prophylaxis of dyslipidemia, low HDL cholesterolemia, arteriosclerosis or coronary heart disease.

27. The use according to claim 24, wherein the medicament is for the treatment or prophylaxis of dyslipidemia.

28. The use according to claim 24, wherein the medicament is for the treatment or prophylaxis of low HDL cholesterolemia.

29. The use according to claim 24, wherein the medicament is for the treatment or prophylaxis of arteriosclerosis.

30. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof for as a medicament.

31. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof, for use in the treatment of dyslipidemia, hypercholesterolemia, low HDL cholesterolemia, high LDL cholesterolemia, hypertriglyceridemia, arteriosclerosis, arteriosclerotic heart disease, coronary heart disease, cerebrovascular disease, peripheral vascular disease or obesity.

32. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof, for use in the treatment of dyslipidemia, low HDL cholesterolemia, arteriosclerosis or coronary heart disease.

33. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof, for use in the treatment of dyslipidemia.

34. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof, for use in the treatment of low HDL cholesterolemia.

35. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof, for use in the treatment of arteriosclerosis.

36. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof for use in the treatment or prophylaxis of a disease caused by a

decrease in the blood concentration of HDL cholesterol.

37. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof for use in the treatment or prophylaxis of a disease caused by an increase in the blood concentration of LDL cholesterol.

38. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof for use in inhibiting CETP.

39. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof for use in increasing the concentration of HDL cholesterol.

40. A compound according to any one of claims 1 to 22 or a pharmacologically acceptable salt thereof for use in decreasing the concentration of LDL cholesterol.